{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:26:46Z","timestamp":1773682006340,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1111\/ijcp.12964","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T10:36:49Z","timestamp":1494585409000},"page":"e12964","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?"],"prefix":"10.1155","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[{"name":"New York Medical College; Valhalla NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"10.1111\/ijcp.12964-BIB0001|ijcp12964-cit-0001","unstructured":"Neurocrine Biosciences INGREZZA (valbenazine) capsules, for oral use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209241lbl.pdf"},{"key":"10.1111\/ijcp.12964-BIB0002|ijcp12964-cit-0002","unstructured":"Neurocrine Biosciences Neurocrine Announces FDA Approval of INGREZZA (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) http:\/\/www.prnewswire.com\/news-releases\/neurocrine-announces-fda-approval-of-ingrezza-tm-valbenazine-capsules-as-the-first-and-only-approved-treatment-for-adults-with-tardive-dyskinesia-td-300438338.html"},{"key":"10.1111\/ijcp.12964-BIB0003|ijcp12964-cit-0003","unstructured":"Neurocrine Biosciences Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 http:\/\/phoenix.corporate-ir.net\/phoenix.zhtml?c=68817&p=RssLanding&cat=news&id=2246000"},{"key":"10.1111\/ijcp.12964-BIB0004|ijcp12964-cit-0004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1111\/ijcp.12964-BIB0005|ijcp12964-cit-0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1111\/ijcp.12964-BIB0006|ijcp12964-cit-0006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1345\/aph.1P312","article-title":"Tetrabenazine for the treatment of tardive dyskinesia","volume":"45","author":"Leung","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ijcp.12964-BIB0007|ijcp12964-cit-0007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ijcp.12805","article-title":"Breakthrough drugs for the interface between psychiatry and neurology","volume":"70","author":"Citrome","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12964-BIB0008|ijcp12964-cit-0008","unstructured":"Teva Pharmaceuticals Teva Announces FDA Approval of AUSTEDO (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease http:\/\/www.businesswire.com\/news\/home\/20170403006578\/en\/"},{"key":"10.1111\/ijcp.12964-BIB0009|ijcp12964-cit-0009","unstructured":"Teva Pharmaceuticals AUSTEDO (deutetrabenazine) tablets, for oral use. Prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208082s000lbl.pdf"},{"key":"10.1111\/ijcp.12964-BIB0010|ijcp12964-cit-0010","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov Disord"},{"key":"10.1111\/ijcp.12964-BIB0011|ijcp12964-cit-0011","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"16 Suppl 1","key":"10.1111\/ijcp.12964-BIB0012|ijcp12964-cit-0012","doi-asserted-by":"crossref","first-page":"S27.001","DOI":"10.1212\/WNL.86.16_supplement.S27.001","article-title":"Open-label extension of kinect: a phase 2 study of valbenazine (NBl-98854) for Tardive Dyskinesia","volume":"86","author":"Bari","year":"2016","journal-title":"Neurology"},{"key":"10.1111\/ijcp.12964-BIB0013|ijcp12964-cit-0013","first-page":"S212","article-title":"Safety and tolerability of valbenazine (NBl-98854) in subjects with tardive dyskinesia: results of long-term exposure data from three studies","volume":"41","author":"Remington","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/ijcp.12964-BIB0014|ijcp12964-cit-0014","first-page":"S213","article-title":"Efficacy of valbenazine (NBl-98854) in subjects with tardive dyskinesia: results of a long-term extension study (KINECT 3 extension)","volume":"41","author":"Grigoriadis","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"S1","key":"10.1111\/ijcp.12964-BIB0015|ijcp12964-cit-0015","first-page":"43","article-title":"In vitro pharmacologic characteristics of valbenazine and its metabolites","volume":"5","author":"Grigoriadis","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1111\/ijcp.12964-BIB0016|ijcp12964-cit-0016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.12964-BIB0017|ijcp12964-cit-0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.12964-BIB0018|ijcp12964-cit-0018","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12964-BIB0019|ijcp12964-cit-0019","unstructured":"Remington G Lindenmayer JP Burke J Aurora B O'Brien CF Tardive dyskinesia and valbenazine (NBI-98854) response as a function of concomitant antipsychotic use"},{"key":"10.1111\/ijcp.12964-BIB0020|ijcp12964-cit-0020","unstructured":"Josiassen RC Remington G Burke J Siegert S Aurora B Valbenazine (NBI-98854) is effective for treating tardive dyskinesia in individuals with schizophrenia or mood disorder"},{"key":"10.1111\/ijcp.12964-BIB0021|ijcp12964-cit-0021","unstructured":"Josiassen R Kane J Burke J Jimenez R Siegert S Liang G Valbenazine (NBI-98854) for the Treatment of Tardive Dyskinesia: Analysis by Underlying Psychiatric Diagnosis in Phase III KINECT 3 Study"},{"key":"10.1111\/ijcp.12964-BIB0022|ijcp12964-cit-0022","unstructured":"Kane J Josiassen R Burke J Jimenez R Siegert S Liang G Response to Treatment with Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia"},{"key":"10.1111\/ijcp.12964-BIB0023|ijcp12964-cit-0023","unstructured":"Jimenez R Shiwach R Bari M O'Brien CF Kinect Extension: 12-week Treatment of Tardive Dyskinesia with NBI-98854"},{"key":"10.1111\/ijcp.12964-BIB0024|ijcp12964-cit-0024","unstructured":"Lindenmayer JP Josiassen RC Burke J Siegert S Aurora B Psychiatric stability maintained in tardive dyskinesia subjects treated with valbenazine"},{"key":"10.1111\/ijcp.12964-BIB0025|ijcp12964-cit-0025","unstructured":"Lundbeck XENAZINE (tetrabenazine) tablets, for oral use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021894s010lbl.pdf"},{"key":"10.1111\/ijcp.12964-BIB0026|ijcp12964-cit-0026","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"J Expert Rev Neurother"},{"key":"10.1111\/ijcp.12964-BIB0027|ijcp12964-cit-0027","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"10.1111\/ijcp.12964-BIB0028|ijcp12964-cit-0028","first-page":"1","article-title":"Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders","volume":"13","author":"Citrome","year":"2007","journal-title":"Am J Manag Care"},{"key":"10.1111\/ijcp.12964-BIB0029|ijcp12964-cit-0029","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm","volume":"37","author":"Citrome","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12964-BIB0030|ijcp12964-cit-0030","unstructured":"Helfand C Neurocrine goes high-$60K-plus high-with price for new movement drug Ingrezza http:\/\/www.fiercepharma.com\/marketing\/neurocrine-goes-high-60k-plus-high-price-for-new-movement-drug-ingrezza"},{"key":"10.1111\/ijcp.12964-BIB0031|ijcp12964-cit-0031","unstructured":"Helfand C Hungry for brand sales, Teva undercuts generics with new, $60K Huntington's med Austedo http:\/\/www.fiercepharma.com\/pharma\/hungry-for-specialty-sales-teva-undercuts-generics-new-huntington-s-med-austedo"},{"key":"10.1111\/ijcp.12964-BIB0032|ijcp12964-cit-0032","first-page":"42","article-title":"Beyond PubMed: searching the \u201cGrey Literature\u201d for clinical trial results","volume":"11","author":"Citrome","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"10.1111\/ijcp.12964-BIB0033|ijcp12964-cit-0033","unstructured":"Food and Drug Administration NDA 209241 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/209241Orig1s000ltr.pdf"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.12964\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T02:43:23Z","timestamp":1719197003000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12964","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,12]]}}}